Kymera Therapeutics, Inc. · NASDAQ:KYMR
Booth Bruce sold 6,000 Kymera Therapeutics, Inc. shares (Form 4)
Traded Apr 22, 2026 · Filed Apr 24, 2026
On Apr 22, 2026, Booth Bruce (Director) sold 6,000 Kymera Therapeutics, Inc. shares at an average US$89.96 for US$540K under a trading plan, leaving 674,944 shares. Filed Apr 24, 2026 (Form 4).
- Sold
- 6,000 shares
- Price
- US$89.96 average (US$89.96 to US$90.08)
- Value
- US$540K
- Holding after
- 674,944 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Common Stock | Option exercise | 5,641 | US$14.18 | 5,641 | Direct |
| Apr 22, 2026 | Common Stock | Option exercise | 259 | US$20.00 | 5,900 | Direct |
| Apr 22, 2026 | Common Stock | Sale | 5,900 | US$89.96 | 0 | Direct |
| Apr 22, 2026 | Common Stock | Sale | 88 | US$90.08 | 3,899,829 | Indirect |
| Apr 22, 2026 | Common Stock | Sale | 12 | US$90.08 | 674,944 | Indirect |
Source
Related
- Kymera Therapeutics, Inc.
- Booth Bruce
- Kymera Therapeutics, Inc. shareholders
- Form 4/A · Booth Bruce · Jul 2, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026